Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis

Journal of Clinical Oncology

Volumn 20, Issue 3, 2002, Pages 833-841

  Shariat, Shahrokh F ^a   Lamb, Dolores J ^a   Kattan, Michael W ^a   Nguyen, Cuong ^a   Kim, JaHong ^a   Beck, Josie ^a   Wheeler, Thomas M ^a   Slawin, Kevin M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE METASTASIS; CANCER GROWTH; CANCER INVASION; CONTROLLED STUDY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; TUMOR VOLUME;

DISEASE PROGRESSION; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; LYMPHATIC METASTASIS; MALE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0036468136     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.3.833     Document Type: Article

References (58)

1. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-betal on programmed cell death through a p53- and IGF-independent mechanism
2. Overexpression of insulin-like growth factor-binding protein-2 results in increased tumorigenic potential in Y-1 adrenocortical tumor cells
3. Novel strategy for growth inhibition of human prostatic cancer cells: Endogeneous IGFBP-2 suppression
4. Anti-IGFBP-2 suppresses prostate tumor growth in nude mice
5. IGFBP-2 stimulates prostate cancer cell growth by an IGF-independent mechanism involving interactions with novel protein partners
6. Expression of insulin-like growth factor I (IGF-I) in female breast cancer as related to established prognostic factors and long-term prognosis
7. Prognostic significance of insulin-like growth factor-binding protein expression in axillary lymph node-negative breast cancer
8. Insulin-like growth factor-II as a prognostic factor in pulmonary adenocarcinoma
9. Expression of insulinlike growth factor-2 can predict the prognosis of human colorectal cancer patients: Correlation with tumor progression, proliferative activity and survival
10. Immunohistochemical localization of insulin-like growth factor binding proteins 2 and 3 in prostate tissue: Clinical correlations
11. Insulin-like growth factor-binding protein-2 and -3 expression in benign human prostate epithelium, prostate intraepithelial neoplasia, and adenocarcinoma of the prostate
12. Differential expression of insulin-like growth factor binding proteins in high versus low Gleason score prostate cancer
13. Expression of the insulin-like growth factor system and cancer progression in hormone-treated prostate cancer patients
14. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer
15. Increased circulating levels of insulin-like growth factor-I and decreased circulating levels of insulin-like growth factor binding protein-1 in postmenopausal women with endometrial cancer
16. Plasma levels of insulin-like growth factor-I and lung cancer risk: A case-control analysis
17. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3
18. Plasma insulinlike growth factor-I and prostate cancer risk: A prospective study
19. Insulin-like growth factor 1 and prostate cancer risk: A population-based, casecontrol study
20. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: A prospective study
21. Correlation of preoperative plasma IGF-I levels with pathologic parameters and progression in patients undergoing radical prostatectomy
22. Serum insulin-like growth factor-I is not a useful marker of prostate cancer
23. Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen
24. The significance of serum levels of insulin-like growth factor-1 in patients with prostate cancer
25. Low serum insulin-like growth factor 1 (IGF-1): A significant association with prostate cancer
26. Longitudinal screening for prostate cancer with prostate-specific antigen
27. Fresh tissue harvest for research from prostatectomy specimens
28. A comparison of the morphological features of cancer arising in the transition zone and in the peripheral zone of the prostate
29. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume
30. Production of immunoreactive insulin-like growth factor-I (IGF-I) and IGF-I binding proteins by human lung tumours
31. Increased insulin-like growth factor binding protein-2 (IGFBP-2) gene expression and protein production lead to high IGFBP-2 content in malignant ovarian cyst fluid
32. Insulin-like growth factor (IGF)-I, -II and IGF-binding proteins in the cyst fluid of a patient with astrocytoma
33. Insulin-like growth factor (IGF)-I, -II and IGF binding protein-2 (IGFBP-2) in the plasma of children with Wilms' tumour
34. Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors
35. Elevated serum insulinlike growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer
36. Alterations in serum levels of insulin-like growth factors and insulin-like growthfactor-binding proteins in patients with colorectal cancer
37. Insulin-like growth factor-I (IGF-I) and IGF-binding protein-2 are increased in cyst fluids of epithelial ovarian cancer
38. Elevated serum insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: Correlation with cancer antigen 125 and tumor-associated trypsin inhibitor
39. Elevated serum levels of IGFBP-2 found in children suffering from acute leukaemia is accompanied by the occurrence of IGFBP-2 mRNA in the tumour clone
40. Insulin-like growth factor-binding protein-2 concentrations in cerebrospinal fluid and serum of children with malignant solid tumors or acute leukemia
41. Serum levels of insulin-like growth factor-I, -II and insulin-like growth factor binding proteins -2 and -3 in children with acute lymphoblastic leukaemia
42. Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: Correlation with serum prostate-specific antigen
43. Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients
44. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia
45. The RIA for IGFBP-2 in man: A meager catch?
46. Prostate specific antigen and Gleason grade: An immunohistochemical study of prostate cancer
47. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: A novel prostate cancer marker
48. Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma
49. Natural history of progression after PSA elevation following radical prostatectomy
50. Insulin-like growth factor binding protein-3 induces apoptosis in MCF7 breast cancer cells
51. Quantitative immunohistochemical analysis of insulin-like growth factor binding protein-3 in human prostatic adenocarcinoma: A prognostic study
52. Bone growth factors
53. Insulin-like growth factors and bone: The osteoporosis connection
54. Low bone mineral density in adults with previous hypothalamic-pituitary tumors: Correlations with serum growth hormone responses to GH-releasing hormone, insulin-like growth factor I, and IGF binding protein 3
55. Isolation of an inhibitory insulin-like growth factor (IGF) binding protein from bone cell-conditioned medium: A potential local regulator of IGF action
56. Intact but not truncated insulin-like growth factor binding protein-3 (IGFBP-3) blocks IGF I-induced stimulation of osteoblasts: Control of IGF signaling to bone cells by IGFBP-3-specific proteolysis?
57. Correlation of the osteoblastic phenotype with prostate-specific antigen expression in metastatic prostate cancer: Implications for paracrine growth
58. Inverse relation between prostate-specific antigen and insulin-like growth factor-binding protein 3 in bone metastases and serum of patients with prostate cancer